An Open-Label Multicenter Study to Evaluate the Pharmacokinetics Safety and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects with Genotypes 1 ? 6 Chronic Hepatitis C Virus (HCV) Infection (DORA)
-
- STATUS
- Not Recruiting
Summary
The purpose of this study is to confirm the investigational drug (glecaprevir and pibrentasvir) doses in children who are between the ages of 3 to 18 years old at the time of enrollment and to determine if the study drugs are safe and able to reduce the amount of hepatitis C virus (HCV) in the blood.
Description
The purpose of this study is to confirm the investigational drug (glecaprevir and pibrentasvir) doses in children who are between the ages of 3 to 18 years old at the time of enrollment and to determine if the study drugs are safe and able to reduce the amount of hepatitis C virus (HCV) in the blood.
Details
| Condition | hepatitis C |
|---|---|
| Age | 3years - 18years |
| Clinical Study Identifier | TX9002 |
| Last Modified on | 19 February 2024 |
Similar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.